Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes

References

• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570–2581
   PubMed Web of Science ®Google Scholar
• Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008;51:385–390
   PubMed Web of Science ®Google Scholar
• Larsen SB, Neergaard-Petersen S, Grove EL, Kristensen SD, Hvas AM. Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. Thromb Haemost 2012;108:140–147
   PubMed Web of Science ®Google Scholar
• Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res 2010;126:e318–e322
   Web of Science ®Google Scholar
• Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009;30:426–435
   PubMed Web of Science ®Google Scholar
• Wurtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, Hvas AM, Kristensen SD. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv 2010;3:828–835
   PubMed Web of Science ®Google Scholar
• Meves SH, Hummel T, Endres HG, Maybock N, Kaiser AF, Schroder KD, Rudiger K, Overbeck U, Mumme A, Mugge A, et al. Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD. J Thromb Thrombolysis 2013 [Epub ahead of print]
   Google Scholar
• Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336:195–198
   PubMed Web of Science ®Google Scholar
• Rocca B, Dragani A, Pagliaccia F. Identifying determinants of variability to tailor aspirin therapy. Expet Rev Cardiovasc Ther 2013;11:365–379
   PubMedGoogle Scholar
• Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 2012;18:5344–5361
   PubMed Web of Science ®Google Scholar
• Guthikonda S, Lev EI, Patel R, Delao T, Bergeron AL, Dong JF, Kleiman NS. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007;5:490–496
   PubMed Web of Science ®Google Scholar
• Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595–3603
   PubMed Web of Science ®Google Scholar
• Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, Sideris G, Sollier CB, Drouet L. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011;105:336–344
   PubMed Web of Science ®Google Scholar
• Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost 2011;106:491–499
   PubMed Web of Science ®Google Scholar
• Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, Tomasello SD, Capranzano P, Seecheran N, Darlington A, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Intervent 2011;4:180–187
   PubMed Web of Science ®Google Scholar
• Dillinger JG, Drissa A, Sideris G, Bal dit Sollier C, Voicu S, Manzo Silberman S, Logeart D, Drouet L, Henry P. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J 2012;164:600–606
   PubMed Web of Science ®Google Scholar
• Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012;10:1220–1230
   PubMed Web of Science ®Google Scholar
• Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L, Trifiró E, Mattiello T, Pitocco D, Liuzzo G, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J 2009;30:1279–1286
   PubMed Web of Science ®Google Scholar
• Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009;101:151–156
   PubMed Web of Science ®Google Scholar
• Schmidt M, Maeng M, Jakobsen CJ, Madsen M, Thuesen L, Nielsen PH, Botker HE, Sorensen HT. Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. Clin Epidemiol 2010;2:137–144
   PubMedGoogle Scholar
• Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006;95:652–658
   PubMed Web of Science ®Google Scholar
• Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008;99:930–935
   PubMed Web of Science ®Google Scholar
• Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, Delao T, Granada JF, Dong JF, Kleiman NS, Lev EI. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52:743–749
   PubMed Web of Science ®Google Scholar
• Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, Kropiwnicka A, Drzewoski J. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) – its relation to metabolic control. Thromb Res 2004;113:101–113
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Standl E, Strotmann HJ, Schulze J, Hohberg C, Lubben G, Pahler S, Schondorf T, Forst T. Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus. Clin Chem Lab Med 2006;44:556–560
   PubMed Web of Science ®Google Scholar
• Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. Thromb Haemost 2013;109:920–929
   PubMedGoogle Scholar
• Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 2005;57(Suppl):42–58
   PubMedGoogle Scholar
• Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, Kristensen SD. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010;103:1245–1253
   PubMed Web of Science ®Google Scholar
• Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing Multiplate™ whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007;18:199–206
   PubMed Web of Science ®Google Scholar
• Jámbor C, Weber CF, Gerhardt K, Dietrich W, Spannagl M, Heindl B, Zwissler B. Whole Blood Multiple Electrode Aggregometry Is a Reliable Point-of-Care Test of Aspirin-Induced Platelet Dysfunction. Anesth Analg 2009;109:25–31
   PubMed Web of Science ®Google Scholar
• Meen O, Brosstad F, Liestol K, Kunszt G, Bendz B, Wettergreen M, Schjelderup NM, Andreassen T, Erikssen G. Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction. Scand J Clin Lab Invest 2012;72:318–325
   Google Scholar